Personalized immune cell therapy aims to clear stubborn COVID-19 infections
NCT ID NCT07690943
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study tests a treatment called LB-DTK-COV19, made from a patient's own immune cells, for people who have had COVID-19 symptoms or a positive test for more than 21 days. Participants receive two infusions of their personalized T cells, two weeks apart, and are followed for six months. The goal is to see if the treatment is safe, reduces viral levels, and improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LB-DTK-COV19 (a personalized T cell therapy made from the patient's own immune cells)
- What this could lead to
- If it works, this could offer a treatment for people with long COVID who still carry the virus, potentially clearing the infection and relieving symptoms.
- What could go wrong
- This is a very small early-stage trial with only 13 participants, so results may not apply broadly. The therapy is complex and may cause side effects or fail to reduce viral levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Catholic University of Korea Seoul St.Mary's Hospital
Seoul, 06591, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain fog after COVID: can two common drugs clear it?
- Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
- Can COVID-19 and emergency surgery be safely managed together? a massive hospital study seeks answers
- Text or call? study tests best way to boost COVID shots in schools
- Fish oil and Body's own healing molecules could lift long COVID depression
- 13,000 volunteers shed light on who gets sick from COVID-19